VRTX Q3 2020 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+62.0% YoY

Gross Profit

$1.4B87.9% margin

Operating Income

$672M43.7% margin

Net Income

$667M43.4% margin

EPS (Diluted)

$2.53

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$908M

Free Cash Flow

$733M

Stock-Based Comp.

$100M

Balance Sheet

Total Assets

$11.3B

Total Liabilities

$3.2B

Stockholders' Equity

$8.1B

Cash & Equivalents

$5.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$950M	+62.0%
Gross Profit	$1.4B	$818M	+65.3%
Operating Income	$672M	$99M	+576.8%
Net Income	$667M	$58M	+1060.4%

Revenue Segments

TRIKAFTA/KAFTRIO

$960M63%

ORKAMBI

$226M15%

KALYDECO

$194M13%

SYMDEKO/SYMKEVI

$156M10%

Geographic Segments

UNITED STATES

$1.2B80%

Europe

$251M16%

Other, Non U.S.

$62M4%